The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
The Effect of Incentive-Based Formularies on Prescription-Drug Utilization and Spending
Open accessAbstract
BACKGROUND: Many employers and health plans have adopted incentive-based formularies in an attempt to control prescription-drug costs. METHODS: We used claims data to compare the utilization of and spending on drugs in two employer-sponsored health plans that implemented changes in formulary administration with those in comparison groups of enrollees covered by the same insurers. One plan simultaneously switched from a one-tier to a three-tier formulary and increased all enrollee copayments for medications. The second switched from a two-tier to a three-tier formulary, changing only the copayments for tier-3 drugs. We examined the utilization of angiotensin-converting-enzyme (ACE) inhibitors, proton-pump inhibitors, and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins). RESULTS: Enrollees covered by the employer that implemented more dramatic changes experienced slower growth than the comparison group in the probability of the use of a drug and a major shift in spending from the plan to the enrollee. Among the enrollees who were initially taking tier-3 statins, more enrollees in the intervention group than in the comparison group switched to tier-1 or tier-2 medications (49 percent vs. 17 percent, P<0.001) or stopped taking statins entirely (21 percent vs. 11 percent, P=0.04). Patterns were similar for ACE inhibitors and proton-pump inhibitors. The enrollees covered by the employer that implemented more moderate changes were more likely than the comparison enrollees to switch to tier-1 or tier-2 medications but not to stop taking a given class of medications altogether. CONCLUSIONS: Different changes in formulary administration may have dramatically different effects on utilization and spending and may in some instances lead enrollees to discontinue therapy. The associated changes in copayments can substantially alter out-of-pocket spending by enrollees, the continuation of the use of medications, and possibly the quality of care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A heteroskedasticity-consistent covariance matrix estimator and a direct test for heteroskedasticity
White, H. (1980) · Econometrica · doi:10.2307/1912934 · Cited by 25,861
(1979) · Medical Entomology and Zoology · Cited by 11,252
(1967) · Project Euclid (Cornell University) · Cited by 4,720
Health insurance and the demand for medical care: evidence from a randomized experiment.
Manning, W. G., Newhouse, J. P., Duan, N., Keeler, E. B., Leibowitz, A. A., & Marquis, M. S. (1987) · PubMed · Cited by 2,478
Employer Drug Benefit Plans and Spending on Prescription Drugs
Joyce, G. F. (2002) · JAMA · doi:10.1001/jama.288.14.1733 · Cited by 228
Effect of a Three-Tier Prescription Copay on Pharmaceutical and Other Medical Utilization
Motheral, B., & Fairman, K. A. (2001) · Medical Care · doi:10.1097/00005650-200112000-00005 · Cited by 161
Job-Based Health Benefits In 2002: Some Important Trends
Gabel, J. R., Levitt, L., Holve, E., Pickreign, J. D., Whitmore, H., Dhont, K., Hawkins, S., & Rowland, D. (2002) · Health Affairs · doi:10.1377/hlthaff.21.5.143 · Cited by 86
Effect of Tiered Prescription Copayments on the Use of Preferred Brand Medications
Rector, T. S., Finch, M. D., Danzon, P. M., et al. (2003) · Medical Care · doi:10.1097/01.mlr.0000053022.47132.82 · Cited by 85
Huskamp, H. A., Epstein, A. M., & Blumenthal, D. (2003) · Health Affairs · doi:10.1377/hlthaff.22.3.149 · Cited by 66
Self-citationThe effect of a closed formulary on prescription drug use and costs.
Motheral, B., & Henderson, R. R. (2000) · PubMed · Cited by 29
D’Agostino (1998) · doi:10.1002/(sici)1097-0258(19981015)17:19<2265::aid-sim918>3.0.co;2-b
Cited by
Goldman, D. P., Joyce, G. F., & Zheng, Y. (2007) · JAMA · doi:10.1001/jama.298.1.61 · Cited by 874
Pharmacy Benefits and the Use of Drugs by the Chronically Ill
Goldman, D. P. (2004) · JAMA · doi:10.1001/jama.291.19.2344 · Cited by 530
Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia
Dusetzina, S. B., Winn, A. N., Abel, G. A., Huskamp, H. A., & Keating, N. L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.9123 · Cited by 500
Self-citationCohen, J. D., Brinton, E. A., Ito, M. K., & Jacobson, T. A. (2012) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2012.03.003 · Cited by 486
Dhalla, I. A., Mamdani, M. M., Sivilotti, M. L. A., Kopp, A., Qureshi, O., & Juurlink, D. N. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.090784 · Cited by 438
Metadata
- Authors
- Huskamp, H. A., Deverka, P. A., Epstein, A. M., Epstein, R. S., McGuigan, K. A., & Frank, R. G.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-12-04
- Volume
- 349
- Issue
- 23
- Pages
- 2224-2232
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2041837876
- Cited by
- 334
- References
- 11
- FWCI
- 69.20
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.